Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Relmada Therapeutics ( (RLMD) ) is now available.
On December 12, 2025, Relmada Therapeutics‘ Board of Directors approved amended employment agreements for its executive officers, effective January 1, 2026. The agreements include salary increases for executives and detailed severance packages in cases of termination, highlighting the company’s commitment to retaining key leadership during potential changes in control.
The most recent analyst rating on (RLMD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for central nervous system disorders.
Average Trading Volume: 1,063,541
Technical Sentiment Signal: Buy
Current Market Cap: $297.7M
Learn more about RLMD stock on TipRanks’ Stock Analysis page.